Assessment of Phase 3 Randomized Clinical Trials Including Patients With Leptomeningeal Disease: A Systematic Review

Alisha E Sharma; Kathryn Corbett; Hany Soliman; Arjun Sahgal; Sunit Das; Mary Jane Lim-Fat; Katarzyna J Jerzak

doi:10.1001/jamaoncol.2022.7364

Assessment of Phase 3 Randomized Clinical Trials Including Patients With Leptomeningeal Disease: A Systematic Review

JAMA Oncol. 2023 Apr 1;9(4):566-567. doi: 10.1001/jamaoncol.2022.7364.

Authors

Alisha E Sharma¹, Kathryn Corbett², Hany Soliman³, Arjun Sahgal³, Sunit Das^{2

4}, Mary Jane Lim-Fat⁵, Katarzyna J Jerzak^{2

6}

Affiliations

¹ Michael G DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.
² University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.
³ Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
⁴ Division of Neurosurgery, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
⁵ Division of Neurology, Department of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
⁶ Division of Medical Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada.

No abstract available

Plain language summary

This systematic review examines the proportion of patients with leptomeningeal disease included in phase 3 randomized clinical trials for patients with metastatic breast cancer, lung cancer, and melanoma.

Publication types

Systematic Review

MeSH terms

Clinical Trials, Phase III as Topic
Humans
Randomized Controlled Trials as Topic*